Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis
-
Published:2024
Issue:4
Volume:41
Page:87-102
-
ISSN:0743-4863
-
Container-title:Critical Reviews™ in Therapeutic Drug Carrier Systems
-
language:en
-
Short-container-title:Crit Rev Ther Drug Carrier Syst
Author:
Dwivedi Shradha Devi,Yadav Krishna,Bhoi Anita,Sahu Keshav Kant,Sangwan Neelam,Singh Deependra,Singh Manju Rawat
Abstract
Rheumatoid arthritis (RA) is a chronic symmetrical systemic disorder that not only affects joints but also other organs such as heart, lungs, kidney, and liver. Approximately there is 0.5%-1% of the total population affected by RA. RA pathogenesis still remains unclear due to which its appropriate treatment is a challenge. Further, multitudes of factors have been reported to affect its progression i.e. genetic factor, environmental factor, immune factor, and oxidative factor. Therapeutic approaches available for the treatment of RA include NSAIDs, DMARDs, enzymatic, hormonal, and gene therapies. But most of them provide the symptomatic relief without treating the core of the disease. This makes it obligatory to explore and reach the molecular targets for cure and long-term relief from RA. Herein, we attempt to provide extensive overlay of the new targets for RA treatment such as signaling pathways, proteins, and receptors affecting the progression of the disease and its severity. Precise modification in these targets such as suppressing the notch signaling pathway, SIRT 3 protein, Sphingosine-1-phosphate receptor and stimulating the neuronal signals particularly efferent vagus nerve and SIRT 1 protein may offer long term relief and potentially diminish the chronicity. To target or alter the novel molecules and signaling pathway a specific delivery system is required such as liposome, nanoparticles and micelles and many more. Present review paper discusses in detail about novel targets and delivery systems for treating RA.
Reference167 articles.
1. Srivastava S, Singh D, Patel S, Parihar AKS, Singh MR. Novel carters and targeted approaches: Way out for rheumatoid arthritis quandrum. J Drug Deliv Sci Technol. 2017;40:125-35. 2. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15. 3. Srivastava S, Patel S, Singh D, Singh MR. Rationalized insights on causes of rheumatoid arthritis in the elderly and women: Special emphasis on treatment strategies. Crit Rev Ther Drug Carrier Syst. 2017;34(2):97-147. 4. Regueiro C, Rodriguez-Rodriguez L, Lopez-Mejias R, Nuno L, Triguero-Martinez A, Perez-Pampin E, Corrales A, Villalba A, Lopez-Golan Y, Abasolo L, Remuzgo-Martinez S, Ortiz AM, Herranz E, Martinez-Feito A, Conde C, Mera-Varela A, Balsa A, Gonzalez-Alvaro I, Gonzalez-Gay MA, Fernandez-Gutierrez B, Gonzalez A. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Sci Rep. 2020;10(1):3355. 5. Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39(4):437-46.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|